Cargando…
A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challengin...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868745/ https://www.ncbi.nlm.nih.gov/pubmed/31752667 http://dx.doi.org/10.1186/s12864-019-6086-2 |
_version_ | 1783472334367096832 |
---|---|
author | Li, Xin Shi, Gengen Chu, Qingsong Jiang, Wenbin Liu, Yixin Zhang, Sainan Zhang, Zheyang Wei, Zixin He, Fei Guo, Zheng Qi, Lishuang |
author_facet | Li, Xin Shi, Gengen Chu, Qingsong Jiang, Wenbin Liu, Yixin Zhang, Sainan Zhang, Zheyang Wei, Zixin He, Fei Guo, Zheng Qi, Lishuang |
author_sort | Li, Xin |
collection | PubMed |
description | BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. RESULTS: Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44 and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. CONCLUSIONS: The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases. |
format | Online Article Text |
id | pubmed-6868745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68687452019-12-12 A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas Li, Xin Shi, Gengen Chu, Qingsong Jiang, Wenbin Liu, Yixin Zhang, Sainan Zhang, Zheyang Wei, Zixin He, Fei Guo, Zheng Qi, Lishuang BMC Genomics Research Article BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. RESULTS: Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44 and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. CONCLUSIONS: The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases. BioMed Central 2019-11-21 /pmc/articles/PMC6868745/ /pubmed/31752667 http://dx.doi.org/10.1186/s12864-019-6086-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Li, Xin Shi, Gengen Chu, Qingsong Jiang, Wenbin Liu, Yixin Zhang, Sainan Zhang, Zheyang Wei, Zixin He, Fei Guo, Zheng Qi, Lishuang A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title | A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title_full | A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title_fullStr | A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title_full_unstemmed | A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title_short | A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
title_sort | qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868745/ https://www.ncbi.nlm.nih.gov/pubmed/31752667 http://dx.doi.org/10.1186/s12864-019-6086-2 |
work_keys_str_mv | AT lixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT shigengen aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT chuqingsong aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT jiangwenbin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT liuyixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT zhangsainan aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT zhangzheyang aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT weizixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT hefei aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT guozheng aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT qilishuang aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT lixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT shigengen qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT chuqingsong qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT jiangwenbin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT liuyixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT zhangsainan qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT zhangzheyang qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT weizixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT hefei qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT guozheng qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas AT qilishuang qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas |